0      0

2021 uroLogic Conference


100 - Non-Metastitic Prostate Cancer: The Right Treatment for the Right Patient at the Right Time (Supported by Bayer HealthCare Pharmaceuticals Inc.)


Oct 28, 2021 11:45am ‐ Oct 28, 2021 1:00pm

Description

This session will help urology nurses/APNs understand best practice approaches for identifying non-metastatic prostate cancer patients to ensure optimal patient outcomes.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/31/23.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speakers Conflict of Interest Disclosure:
Leanne Schimke, MSN, CRNP, FNP-C, CUNP – Speakers Bureau, Bayer and Pfizer

Commercial Support and Sponsorship:
Supported by Bayer HealthCare Pharmaceuticals Inc.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be able to discuss the new medications approved in the non-metastatic castrate resistant prostate cancer state, along with the associated side effects.

Speaker(s):

You must be logged in and own this session in order to post comments.